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Abstract
Introduction: The remarkable expansion in availability of antiretroviral therapy (ART) over the past two decades has transformed
HIV infection into a manageable chronic condition. People with HIV infection now live long and healthy lives on treatment that is
simpler, safer and cheaper. According to UNAIDS estimates, the global coverage of ART reached 46% in 2015, resulting in a 26%
decrease in annual HIV-related deaths since 2010. Such success has positioned treatment access at the centre of the global HIV
response as a way to prevent mortality, morbidity and HIV transmission through a ‘‘Treat All’’ approach. Continuing expansion of
treatment is needed to further reduce HIV-related mortality. This progress with treatment, however, masks a stagnation in the
estimated annual number of new HIV infections. Continuing levels of HIV incidence despite treatment scale-up stem from
several factors, which should be addressed in order to prevent new infections and decrease the numbers of people requiring
treatment in the future.
Discussion: ART can only reach those already diagnosed, and although it is unclear what proportion of new infections occur
during acute and early infection prior to treatment initiation, phylogenetic studies suggest that it might be substantial. Thus,
better testing approaches to reach the 40% of people with undiagnosed HIV infection as early as possible are critical. New
approaches to reach men, young people and key populations, where HIV risk is highest and HIV prevention, testing and
treatment coverage is lowest, are also needed. Overall coverage of effective prevention interventions remains low, enabling HIV
transmission to occur, or time is required to show population-level effects. For example, the full impact of the medical male
circumcision intervention will be seen once a larger proportion of men in age cohorts with high incidence are circumcised.
Finally, strategically focused pre-exposure prophylaxis interventions have the potential to prevent HIV acquisition among
populations at substantial risk, averting treatment costs in coming years.
Conclusions: The United Nations (UN) targets to end AIDS include the ‘‘90-90-90’’ targets for HIV diagnosis, treatment and viral
suppression. While 90-90-90 has been widely emphasized and adopted by countries and international funders, the focus thus far
has largely been on increasing access to ART  the second ‘‘90.’’ A similar emphasis on achieving UN HIV prevention targets and
adequate funding for meeting these is essential, alongside treatment, in order to reduce population-level incidence and change
the trajectory of the HIV epidemic over the long term.
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Introduction
The HIV response and the outlook for people with HIV looked
very different at the 2016 International AIDS conference
in Durban, South Africa, than it did in 2000 when the 13th
Conference was also held in Durban. Approximately 12,000
people attended the 2000 conference, and Jeffrey Sachs
reinforced the call by the Group of Eight and the World Health
Organization (WHO) for a global fund to fight AIDS, which
was established just over a year later. Nelson Mandela gave
the closing address, where he stated ‘‘this is, as I understand
it, a gathering of human beings concerned about turning
around one of the greatest threats humankind has faced.’’
In the intervening 16 years, a remarkable turnaround has
indeed occurred. HIV is now, as a result of the scale-up in
antiretroviral therapy (ART), a treatable infection, with millions
of people with HIV living long and healthy lives. The Global
Fund to Fight AIDS, Tuberculosis and Malaria has provided
more than $15 billion and the United States President’s
Emergency Plan for AIDS Relief (PEPFAR) has provided more
than $50 billion in HIV funding to support this. The prices of
antiretroviral drugs have reduced substantially and formula-
tions are simpler and safer, and the confirmation of the clinical
benefits of early treatment is recognized with new treatment
recommendations to ‘‘Treat All’’ being widely adopted as
policy [1]. Decentralizing service delivery and task sharing
have also contributed to increasing ART coverage, particularly
across sub-Saharan Africa. The latest UNAIDS report estimates
that the global coverage of ART reached 46% in 2015,
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contributing to a 26% decrease in annual HIV-related deaths
since 2010 [2]. Such success has positioned treatment access
at the centre of the global HIV response as a way to prevent
mortality and morbidity and ongoing HIV transmission to
infants of positive mothers, or to sexual and drug-injecting
partners. To date, this message has been well accepted and
further scale-up of ART coverage is seen as the keystone to
achieve the United Nations (UN) 90-90-90 targets to diagnose
90% of all people with HIV, to treat 90% of those diagnosed
and for 90% of people treated to be virally suppressed [3].
Although this focus and progress on the second of the three
‘‘90s’’ has been critical to reducing morbidity and mortality,
efforts in improving the diagnosis of people with HIV who are
not aware of their status, and in achieving viral suppression
among those on treatment, need further attention.
Despite these achievements, earlier ART and support for
better retention on ART are needed to reduce annual
mortality rates from HIV further, and UNAIDS reports that
there has not been a significant decrease in estimated new
infections since 2010. With approximately 2 million (1.72.2
million) new infections in 2015, it is now estimated that
there are 36.7 million (34.0 million39.8 million) people
with HIV globally [2]. Furthermore, not only are rates of new
adult infections static, but some regions also continue to
experience increases in new infections. In Eastern Europe and
Central Asia, where HIV is primarily concentrated in key
populations, there was an estimated 57% increase in annual
new infections between 2010 and 2015 [2].
Discussion
The limits of treatment as prevention
Although it was anticipated [4], a reduction in new HIV
infections because of the global increase in ART coverage has
not yet been demonstrated and needs to be understood.
At an individual level, two studies found ART to be highly
effective in preventing HIV transmission between partners
[5,6], reporting 96% effectiveness among serodiscordant
heterosexual couples [5] and nearly 100% effectiveness among
virally suppressed serodiscordant heterosexual and male
same-sex partners [6]. This heralded optimism that the
90% preventive effect of ART, which is widely used (or
approximations to it) in modelling, was forecast to result in
the rapid translation of 90% reduction in new HIV infections
at a population level by 2030 [3].
However, large reductions in incidence have not been seen.
Most recently, a large trial assessing the impact of universal
‘‘test and treat’’ on HIV incidence found no reduction in
incidence following the intervention [7]. The increase in ART
coverage over the past five years in East and Southern Africa
has been remarkable, with an estimated 30% increase in ART
coverage, from 24% (2226%) in 2010 to 54% (5058%) in
2015. Although this scale-up has resulted in a 36% decrease
in annual HIV-related deaths in the region, during the same
period, there was no significant decline in estimated new
adult HIV infections [2]. This may be either because it is too
early to see a population-level effect of ART scale-up or
because ART coverage will actually need to be much higher
and sustained, and be of sufficient quality, with achievement
of viral suppression, in order to achieve a substantial reduction
in new infections.
Lack of impact of treatment scale-up on HIV incidence
stems from several factors
First, even under the most optimistic scenarios, it is currently
not possible to identify and treat people early enough after
their infection to prevent further HIV transmission. A
continuing concern is the estimated 40% of all people with
HIV who remain undiagnosed, [8] and are therefore unlinked
to prevention, treatment and care services and continue
to be at risk of transmitting HIV vertically (mother-to-child
transmission) or to sexual and drug-injecting partners. Better
testing approaches which can reach those with undiagnosed
HIV infection, as early in their infection as possible, need
support and funding. These could include medical indicator
condition-guided HIV testing, HIV self-testing and routinely
offering assisted partner notification services to all persons
diagnosed with HIV infection during their interactions with
health services.
Without developing and implementing new approaches to
reach men, young people and key populations where HIV risk
is highest and HIV testing coverage is lowest, the benefits of
testing and linkage to prevention, treatment and care will
continue to be unrealized [9]. This is reflected in the fact
that although ART coverage has increased substantially over
the last decade, the average CD4 cell count at the start of
treatment has only increased modestly [10,11]; many people
still only start ART when they are at an advanced stage
of immunosuppression, implying many years between infec-
tion and initiation of ART.
Even for the relatively limited number of people diagnosed
early following infection, it may not have been early enough
to initiate treatment, achieve viral suppression and prevent
transmission. It is unclear what proportion of new infections
(transmissions) occur during acute and early phases of
HIV infection (before people can be feasibly diagnosed and
started on ART). However, it is clear that despite high ART
coverage in many high-income settings, HIV incidence is not
falling. Phylogenetic analysis of viral sequences suggests that
in the Netherlands 70% of new infections arise from undiag-
nosed people, and 22% during acute and recent HIV infection
[12]. A phylogenetic transmission analysis with matched
epidemiological and clinical data among men who have sex
with men (MSM) in the United Kingdom shows a similar
pattern with recent infection contributing disproportionately
to secondary HIV transmission [13]. In Vancouver, Canada,
it was reported that high ART coverage had resulted in
decreases in community viral load and new HIV diagnoses
[14]; however, the role of increased coverage of comprehen-
sive harm reduction for people who inject drugs in driving
these trends is unclear [15]. Government HIV surveillance
reported little change in new diagnoses among MSM in
British Columbia, Canada [16].
Second, high levels of treatment coverage are not the same
as high levels of virological suppression as emphasized by the
third 90 UN target for testing and treatment. Suboptimal
adherence and high rates of loss to follow-up continue to
influence the overall effectiveness of ART. A recent analysis of
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rates of virological suppression in low- and middle-income
settings found that when loss to follow-up was taken into
consideration, only around 62% of patients starting ART were
virologically suppressed four years after starting ART [17] and
in the United States only two-thirds of people in HIV care had
durable viral suppression during a two-year period [18].
Third, models predicting the impact of ART on HIV inci-
dence at the population level are also predicated on high
levels of coverage of prevention interventions [19]. However,
coverage of key prevention interventions remains too low
and may take time to take effect. For example, the population-
level impact of voluntary medical male circumcision (VMMC),
an effective one-time intervention, is likely to only be fully
realized in coming years once a larger proportion of adolescent
boys and men are circumcised in age cohorts with high
incidence or prior to reaching sexual debut. Similarly, there is a
gap between need and availability of condoms in sub-Saharan
Africa [8].
Fourth, female-controlled prevention options have been
few thus far, although pre-exposure prophylaxis (PrEP) shows
promise for both women and men. Pairing increased treat-
ment access with refocused interventions to prevent new
infections among women will be needed to make the
progress required to turn around the HIV epidemic.
Fifth, key populations, which have continued high HIV inci-
dence, are still faced with social and legal barriers, which
increase their risk of HIV exposure and acquisition and inhibit
access to evidence-basedHIVprevention and treatment services.
For example, despite compelling evidence of the effectiveness of
harm reduction interventions, countries remain reluctant to
implement needle and syringe programmes (NSPs) and opioid
substitution therapy, or to bring them to scale.
Prevention is contextual and often perceived as
‘‘complicated, difficult and boring’’
Interest, prioritization and funding for HIV prevention inter-
ventions and programmes from countries, donors and com-
munities have been inadequate over the last decade. For
example, in 2015, only 7% of the estimated funds required to
reach enough people who inject drugs with evidence-based
prevention services to have an impact on the epidemic was
available from international donors [20].
Significant prevention gains were made in some countries
in East and Southern Africa, such as Uganda and Zimbabwe,
before ART became widely available; paradoxically, these
gains have diminished over the past five years where ART
coverage has increased. National surveys suggest that trends
in indicators associated with higher HIV risk behaviours 
early sexual debut, multiple sexual partners and unprotected
sex  have increased compared with the declines reported in
20002010. Condom availability and funding has decreased
in some settings, with countries recently reporting stock-
outs. As a large new generation of adolescents is emerging,
they often have less knowledge about HIV prevention than
the cohort before them. Yet, today, HIV prevention choices
are more varied and effective than ever before.
Providing effective and acceptable prevention services
across countries and populations is complex. Unlike ART,
where recommendations are universal across populations
and regions, what to offer and how to provide effective and
acceptable prevention varies by population and epidemiolo-
gical context [21]. Human behavioural factors also compound
the successful adoption of prevention interventions, and
often difficult legal and social considerations need to be
addressed for effective service delivery. Furthermore, laws
and policies such as mandatory testing and criminalization
of HIV transmission inhibit HIV test uptake and treatment
access. WHO does not support mandatory testing or laws and
policies which criminalize HIV transmission or behaviours of
key populations.
VMMC is a cost-effective, one-off, permanent, lifelong pre-
vention intervention shown to decrease the risk of hetero-
sexually acquired HIV in men by 60%. By the end of 2015,
14 countries in Africa have delivered a comprehensive HIV
prevention package including circumcision to more than
12 million adolescent boys and men. The impact of VMMC on
HIV incidence, although demonstrated in Uganda, will likely
have been limited to date, but will increase over the next five
years as the circumcised adolescent boys and younger men
become sexually active and reach ages where incidence has
been greatest to date.
An impressive body of evidence confirms that PrEP is highly
effective in preventing HIV acquisition [22] and can be cost-
effective if provided for people at substantial HIV risk. PrEP
programmes are starting to be prioritized for MSM in high-
and middle-income countries, and a national programme
providing PrEP for sex workers was launched in South Africa
in June 2016. PrEP services need to be implemented well
and focused strategically  a balanced approach to creating
demand and delivering PrEP within existing services will be
needed for maximum acceptability and impact. If implemen-
ted well, PrEP programmes will not only provide effective
prevention for those at ongoing substantial risk of infection,
but also reach people at high HIV risk with HIV testing services.
This should increase the diagnoses of new HIV infections and
facilitate linking people with HIV to ART services, as a feasible
approach to identifying and treating people during acute and
early HIV infections to reduce HIV transmission.
Prioritizing key populations
The UNAIDS report also indicates that with the exception of
sub-Saharan Africa, more than 90% of new HIV infections in
other parts of the world in 2014 were among people from
key populations (MSM, sex workers, people who inject drugs,
transgender people, and people in prisons and other closed
settings) and their sexual partners. In sub-Saharan Africa,
these populations accounted for more than 20% of new HIV
infections. Key populations are still not being reached at scale
or with effective HIV prevention, testing and treatment
services despite having the highest rates of HIV incidence
and prevalence.
Some countries continue to prioritize HIV prevention efforts
among the general population even where the prevalence is
very low. Social and cultural unease and legal barriers often
get in the way of accepting the public health impact of
interventions and result in a failure to provide HIV services
to key populations in many countries. Structural and social
determinants of risk, such as violence and criminalization, can
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be addressed through successful prevention programmes
focusing on key populations, although such measures are
perceived to be difficult. However, although the current social
and legal environment makes it often unpopular and difficult
to recognize and support services for key populations, the
HIV response should be driven by epidemiologic evidence in
all countries and should prioritize high-impact interventions
for populations at increased risk of infection. There is the
potential for new interventions whose impact outside of
clinical research has yet to be realized. PrEP is one example
where its implementation at scale may have an important
place in HIV prevention efforts.
People who live in prisons and other closed settings are
often ignored in the response, although they have increased
HIV, tuberculosis and hepatitis prevalence and high rates of risk
behaviours, including injecting drug use and unprotected sex
while incarcerated. Risk behaviours may continue after their
release from prison and return to their communities. There is
also a significant overlap of networks between different key
population groups, with incarceration rates high among people
who inject drugs and sex workers. Investment in HIV preven-
tion programmes in the community can bemade redundant by
a complete lack of services within prisons: while com-
munity-based NSPs are available in 90 countries, only eight
countries provide prison NSPs. Condomprogrammes, available
almost universally in community settings, are only pro-
vided in prisons in 28 countries [23].
Strategic information is being used in awide range of countries
to refocus their HIV resources, to reach key populations and
invest in high-impact interventions. A number of development
agencies are providing incentives for countries to make more
strategic choices in investing their HIV resources. For example,
PEPFAR has announced the establishment of a new invest-
ment fund for key populations, and the Global Fund high-
lights the importance of addressing key populations in the
development of concept notes for funding. Identifying and
scaling up effective and comprehensive prevention and
treatment services for key populations will contribute sig-
nificantly towards reducing the numbers of new HIV infections
over time.
Conclusions
The UN 90-90-90 targets for HIV diagnosis, treatment and
viral suppression have been widely promoted and adopted by
countries and international funders. While the scale-up of
treatment has contributed to saving millions of lives and
reducing major illnesses, there has also been an increasing
expectation that treatment scale-up will have an impact on
HIV incidence at a population level. At a global level, even in
cities such as Amsterdam, London and Paris, where 90-90-90
targets have been reached [24], this has not yet been shown.
These data highlight the need to continue to scale up access
to HIV treatment, as soon as possible after infection, and in
particular for key populations. The promise of ‘‘treatment-as-
prevention’’ is predicated on high coverage of testing and
prevention interventions and high ART adherence and
retention. A similar emphasis and push for the UN prevention
targets and funding for prevention, with specific prevention
packages for different populations, should be embraced
alongside the ART scale-up in order to reduce population-
level incidence and change the trajectory of the HIV epidemic
over the long term.
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